Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amicus Therapeutics Inc (NASDAQ:FOLD)

12.51
Delayed Data
As of Aug 18
 +0.22 / +1.79%
Today’s Change
4.41
Today|||52-Week Range
14.05
+151.71%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.1B

Company Description

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Contact Information

Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury New Jersey 08512
P:(609) 662-2000
Investor Relations:
(609) 662-5000

Employees

Shareholders

Other institutional60.74%
Mutual fund holders48.03%
Individual stakeholders38.18%

Top Executives

John Francis CrowleyChairman & Chief Executive Officer
Bradley L. CampbellPresident & Chief Operating Officer
Chip BairdChief Financial Officer
Enrique DiloneSenior Vice President-Technical Operations
Jay A. BarthChief Medical Officer